Eli LillyIndianapolis, Indiana, United States
Disclosure information not submitted.
SAT-708 - Body Weight Reduction with Orforglipron by Obesity Duration in Adults with Obesity: Post Hoc Analyses of ATTAIN-1 and ATTAIN-2
Saturday, June 13, 20269:30 AM - 4:30 PM CT
MON-727 - Participant-Reported Weight Reduction and Reasons for Continuing or Discontinuing Tirzepatide Treatment: Insights from the PERCEPTIONS Longitudinal Survey at 3 Months
Monday, June 15, 20269:00 AM - 2:00 PM CT
MON-728 - Patient-reported improvements in appetite control, quality of life, and work-related outcomes following tirzepatide treatment for obesity or overweight in the US: Results from 3-month PERCEPTIONS survey
.jpg)
.jpg)